Zoetis Inc.

(New York Stock Exchange)
Back to all articles
Bearish -65

Zoetis Inc. (NYSE: ZTS) Class Action Lawsuit Seeks Recovery - GlobeNewswire

AI-generated analysis

πŸ“… A securities fraud class action lawsuit against Zoetis Inc. (ZTS) is active in the Southern District of New York with a July 27, 2026 deadline for lead plaintiff status.

βš–οΈ The complaint alleges material misstatements regarding product adoption, specifically citing weakening growth for Librela due to FDA safety warnings and market share losses for Simparica Trio, Apoquel, and Cytopoint.

πŸ“‰ Zoetis reported a significant decline in its Companion Animal business in the first quarter of 2026, causing its stock price to fall 21.5% on May 7, 2026.

πŸ—£οΈ Defendants are accused of making materially false statements about the company's business operations and prospects that lacked a reasonable basis during the class period.

πŸ“ž Investors can contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation regarding potential recovery options without cost or obligation.

Risk Factors
  • ⚠️ The lawsuit alleges that Zoetis made materially false and misleading statements concerning the company's product adoption and business prospects during the class period.
  • πŸ“‰ Zoetis reported a significant decline in its Companion Animal business in Q1 2026, which directly caused the stock price to drop 21.5% on May 7, 2026.
  • ⚠️ The complaint asserts that prescription growth for Librela was weakening following FDA safety warnings regarding serious neurological complications.
  • πŸ“‰ Simparica Trio is alleged to be losing significant market share to a lower-priced competitor, impacting revenue stability.
  • ⚠️ Dermatological products Apoquel and Cytopoint are accused of losing market share to competition, further undermining the company's growth narrative.
Full Analysis
A securities fraud class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) in the U.S. District Court for the Southern District of New York, alleging material misstatements regarding product adoption and business prospects between January 14, 2025, and May 6, 2026. The complaint asserts that defendants failed to disclose weakening prescription growth for Librela following FDA safety warnings concerning neurological complications, as well as significant market share losses for Simparica Trio and dermatological products like Apoquel and Cytopoint to lower-priced competitors. The lawsuit highlights a specific catalyst where Zoetis reported its first quarter 2026 financial results on May 7, 2026, revealing a significant decline in its Companion Animal business. This news triggered an immediate 21.5% drop in the company's stock price. The legal filing contends that prior statements about the company's operations and future prospects were materially false or misleading at all relevant times during the class period. Investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, are invited to contact Kessler Topaz Meltzer & Check, LLP by July 27, 2026, to seek lead plaintiff status or discuss recovery options. The firm operates on a contingency fee basis with no cost to investors for the initial case evaluation, while noting that Zoetis may retain counsel of choice or take no action.